Capital International Inc. CA Has $24.03 Million Stock Holdings in Royalty Pharma PLC $RPRX

Capital International Inc. CA grew its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 3.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 681,155 shares of the biopharmaceutical company’s stock after purchasing an additional 19,619 shares during the quarter. Capital International Inc. CA owned about 0.12% of Royalty Pharma worth $24,031,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Royalty Pharma by 367.7% in the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after purchasing an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after buying an additional 13,489 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of Royalty Pharma during the 1st quarter worth about $264,000. Intech Investment Management LLC grew its position in shares of Royalty Pharma by 41.0% during the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares during the period. Finally, Resona Asset Management Co. Ltd. bought a new stake in shares of Royalty Pharma in the 2nd quarter valued at about $3,979,000. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Price Performance

Shares of RPRX opened at $45.97 on Wednesday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40. The stock has a 50 day simple moving average of $42.81 and a 200 day simple moving average of $39.37. Royalty Pharma PLC has a 52-week low of $29.66 and a 52-week high of $47.86. The firm has a market capitalization of $26.52 billion, a PE ratio of 34.05 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The business had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. Sell-side analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th were given a dividend of $0.235 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s payout ratio is currently 69.63%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RPRX. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a research report on Thursday, December 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a research note on Thursday, February 12th. Citigroup increased their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings raised shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $48.67.

Insiders Place Their Bets

In related news, EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $46.78, for a total value of $1,627,522.98. Following the transaction, the chief financial officer owned 45,761 shares of the company’s stock, valued at approximately $2,140,699.58. This trade represents a 43.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 737,078 shares of company stock worth $29,862,002. 18.90% of the stock is currently owned by company insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.